Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone609-619-3990
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.15 million
Profitability
Miscellaneous
Employees56
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable
Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions
What is Outlook Therapeutics' stock symbol?
Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."
When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?
Shares of Outlook Therapeutics reverse split on the morning of Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.
How were Outlook Therapeutics' earnings last quarter?
Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings results on Thursday, December, 19th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.19. The firm earned $5.85 million during the quarter, compared to analyst estimates of $0.63 million. View Outlook Therapeutics' Earnings History.
When is Outlook Therapeutics' next earnings date?
What price target have analysts set for OTLK?
5 brokerages have issued 12-month price objectives for Outlook Therapeutics' stock. Their forecasts range from $4.00 to $12.00. On average, they expect Outlook Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 810.3% from the stock's current price. View Analyst Price Targets for Outlook Therapeutics.
What is the consensus analysts' recommendation for Outlook Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Outlook Therapeutics.
Has Outlook Therapeutics been receiving favorable news coverage?
News stories about OTLK stock have been trending neutral on Wednesday, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Outlook Therapeutics earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Outlook Therapeutics.
Are investors shorting Outlook Therapeutics?
Outlook Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,600,000 shares, an increase of 30.0% from the January 15th total of 2,000,000 shares. Based on an average daily trading volume, of 959,100 shares, the days-to-cover ratio is currently 2.7 days. Currently, 21.4% of the shares of the company are sold short. View Outlook Therapeutics' Current Options Chain.
Who are some of Outlook Therapeutics' key competitors?
Some companies that are related to Outlook Therapeutics include Axcella Health (AXLA), Cidara Therapeutics (CDTX), Surface Oncology (SURF), Applied Genetic Technologies (AGTC), Champions Oncology (CSBR), Acorda Therapeutics (ACOR), Pluristem Therapeutics (PSTI), Pharmacyte Biotech (PMCB), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), INmune Bio (INMB), Genocea Biosciences (GNCA), Vaxart (VXRT), Allena Pharmaceuticals (ALNA) and Curis (CRIS).
What other stocks do shareholders of Outlook Therapeutics own?
Who are Outlook Therapeutics' key executives?
Outlook Therapeutics' management team includes the folowing people:
- Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec., Treasurer & Director (Age 53)
- Dr. Pankaj Mohan, Founder & Director (Age 54)
- Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)
- Mr. Terry Dagnon, Chief Operating Officer (Age 57)
- Rick Gregory, Director of Marketing & Communications
Who are Outlook Therapeutics' major shareholders?
Outlook Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include LVW Advisors LLC (1.45%) and Ladenburg Thalmann Financial Services Inc. (0.15%). Company insiders that own Outlook Therapeutics stock include Kurt J Hilzinger, Lawrence A Kenyon and Randy H Thurman. View Institutional Ownership Trends for Outlook Therapeutics.
Which major investors are buying Outlook Therapeutics stock?
OTLK stock was purchased by a variety of institutional investors in the last quarter, including LVW Advisors LLC and Ladenburg Thalmann Financial Services Inc.. Company insiders that have bought Outlook Therapeutics stock in the last two years include Kurt J Hilzinger, Lawrence A Kenyon and Randy H Thurman. View Insider Buying and Selling for Outlook Therapeutics.
How do I buy shares of Outlook Therapeutics?
Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Outlook Therapeutics' stock price today?
One share of OTLK stock can currently be purchased for approximately $0.99.
How big of a company is Outlook Therapeutics?
Outlook Therapeutics has a market capitalization of $29.76 million and generates $8.15 million in revenue each year. The company earns $-34,520,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Outlook Therapeutics employs 56 workers across the globe.View Additional Information About Outlook Therapeutics.
What is Outlook Therapeutics' official website?
How can I contact Outlook Therapeutics?
Outlook Therapeutics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]
MarketBeat Community Rating for Outlook Therapeutics (NASDAQ OTLK)
MarketBeat's community ratings are surveys of what our community members think about Outlook Therapeutics and other stocks. Vote "Outperform" if you believe OTLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
